158 related articles for article (PubMed ID: 20820968)
1. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
Miyake Y; Okoshi Y; Machino T; Chiba S
Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
[TBL] [Abstract][Full Text] [Related]
2. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Jahnke K; Muldoon LL; Varallyay CG; Lewin SJ; Brown RD; Kraemer DF; Soussain C; Neuwelt EA
Neuro Oncol; 2009 Oct; 11(5):503-13. PubMed ID: 19158414
[TBL] [Abstract][Full Text] [Related]
4. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
5. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
7. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
Kadoch C; Li J; Wong VS; Chen L; Cha S; Munster P; Lowell CA; Shuman MA; Rubenstein JL
Clin Cancer Res; 2014 Feb; 20(4):1029-41. PubMed ID: 24190981
[TBL] [Abstract][Full Text] [Related]
8. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
9. Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma.
Thumrongsiri N; Dana P; Bawab R; Tanyapanyachon P; Treetidnipa C; Saengkrit N; Sathornsumetee S
Biomed Pharmacother; 2022 Jun; 150():112979. PubMed ID: 35461090
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
12. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
[TBL] [Abstract][Full Text] [Related]
13. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
[TBL] [Abstract][Full Text] [Related]
15. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Cheah CY; Seymour JF
Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
[No Abstract] [Full Text] [Related]
16. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
Cornec D; Tempescul A; Querellou S; Hutin P; Pers JO; Jamin C; Bendaoud B; Berthou C; Renaudineau Y; Youinou P
Ann Hematol; 2012 May; 91(5):715-721. PubMed ID: 22083514
[TBL] [Abstract][Full Text] [Related]
17. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
Beum PV; Kennedy AD; Taylor RP
J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
[TBL] [Abstract][Full Text] [Related]
18. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.
Strowd RE; Abuali IA; Grossman SA
CNS Oncol; 2015; 4(3):131-5. PubMed ID: 25905905
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
20. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]